McKesson Corporation (NYSE:MCK) is expanding its specialty healthcare operations through a $5.8 billion acquisition (including debt) of Option Care Health, Inc. (NASDAQ:OPCH), partnering with private equity firm Clayton, Dubilier & Rice to take the infusion-services provider private. Announced on October 6, the transaction values Option Care at $32.05 per share, representing a 37% premium to its previous closing price. CD&R will own 51% of the business, while McKesson will hold 49% and retain the right to acquire its partner’s stake in the future.
The transaction extends McKesson’s strategy of moving beyond traditional pharmaceutical distribution into higher-value healthcare services. For Option Care shareholders, the acquisition provides an opportunity to realize a substantial premium after a period of relatively modest growth. For McKesson investors, however, the more important question is whether expanding into infusion services can generate sufficient earnings and returns to justify the company’s growing acquisition commitments.
McKesson (MCK) ranked #3 on our list of Top 10 Strong Buy Stocks to Invest In. See which two stocks ranked even higher and what sets them apart.
McKesson Is Expanding Beyond Pharmaceutical Distribution
McKesson Corporation has increasingly focused on specialty pharmaceuticals, oncology, and clinical services as growth drivers alongside its core drug distribution operations. The strategy is supported by rising demand for complex medicines, including biologic therapies that require specialized handling, administration, and patient support. Option Care’s home-based and alternate-site infusion network would extend McKesson’s participation further into the treatment process, potentially strengthening relationships with providers, drugmakers, and patients.
That expansion builds on McKesson’s previously announced $2.25 billion agreement to acquire Precision Medicine Group, which is expected to strengthen its oncology and clinical research capabilities, although the financial payoff from its growing specialty-care portfolio remains dependent on successful integration.
The company’s recent financial performance provides a relatively strong foundation for that expansion. In the first quarter of fiscal 2027, McKesson reported revenue of $105.4 billion, exceeding analysts’ expectations of $103.74 billion, while adjusted EPS increased 20% YoY to $9.93. Its U.S. pharmaceutical business generated $86.8 billion in revenue, up 5%, supported partly by higher prescription volumes for specialty medicines. Management subsequently raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00 from $43.80-$44.60, reinforcing expectations for continued earnings growth.
Morgan Stanley analyst Erin Wright views the potential expansion favorably, highlighting Option Care’s position in an attractive but fragmented multispecialty market. The analyst believes the acquisition would broaden McKesson’s specialty healthcare presence, particularly across immunology, neurology, infectious diseases, and rare diseases. Morgan Stanley maintained an Overweight rating and a $977 price target on McKesson, reinforcing its confidence in the company’s broader specialty expansion strategy. McKesson previously completed another major transaction involving private equity. See what analysts said about the stock.
Option Care Brings an Established Network, But Growth Has Been Uneven
Option Care Health, Inc. operates one of the largest independent infusion-services networks in the United States, providing treatments for patients with cancer, autoimmune diseases, serious infections, and other complex conditions. The company served more than 315,000 patients last year through its home-based services and 184 care centers. Its business is positioned to benefit from the growing use of specialty medicines and efforts to shift appropriate treatments away from more expensive hospital settings. Before the takeover announcement, Option Care had already attracted bullish attention from value investors. See what made the stock an intriguing investment opportunity before the $5.8 billion deal.
However, recent results suggest that attractive industry demand has not consistently translated into strong company-level growth. Second-quarter revenue increased 1.9% to $1.44 billion, while adjusted EBITDA rose 3% to $117.5 million. Adjusted diluted EPS increased 9.8% to $0.45, and operating cash flow reached $184 million, representing an improvement from the first quarter, when adjusted EBITDA declined 6.3% and operating activities consumed $12.1 million in cash. Not every investor was convinced by Option Care’s recovery prospects. Find out why one investment fund exited the stock after encountering multiple operational headwinds.
Management had previously acknowledged dissatisfaction with revenue growth momentum and introduced initiatives intended to improve commercial execution. Before withdrawing its 2026 guidance following the acquisition announcement, Option Care had forecast revenue of $5.675 billion-$5.775 billion and adjusted EBITDA of $480 million-$495 million, implying an adjusted EBITDA margin of approximately 8.5% at the midpoint. Those figures demonstrate that Option Care Health, Inc. is generating meaningful operating earnings, but they also show why accelerating patient volumes and improving operating efficiency remain important.
McKesson’s distribution relationships and specialty-care infrastructure could potentially support that recovery. Nevertheless, investors should distinguish between the strategic rationale for combining the businesses and the earnings improvement that has actually been demonstrated. Option Care’s recent growth has been modest, and the acquisition’s success will depend on whether broader commercial relationships can produce measurable financial gains.
The Valuation Debate Differs for McKesson and Option Care
For Option Care Health, Inc., the $32.05-per-share offer has fundamentally changed the near-term investment case. The 37% premium provides shareholders with an opportunity to realize value without waiting for management’s growth initiatives to deliver a sustained earnings recovery. Its forward earnings multiple of 11.22 times is now less informative than the agreed consideration, the probability of closing, and any remaining spread between the market price and the acquisition offer.
Wall Street’s response suggests that analysts view the agreed consideration as a reasonable outcome for Option Care shareholders. On October 7, Barrington analyst Michael Petusky downgraded the stock to Market Perform from Outperform, describing the $32.05-per-share offer as attractive and indicating that a higher competing bid was unlikely. William Blair analyst Matt Larew similarly downgraded Option Care to Market Perform, suggesting the transaction likely followed a formal sale process and that competing offers were not expected.
McKesson Corporation, meanwhile, trades at 19.72 times forward earnings as of October 9. Consensus estimates imply EPS growth of 14.25% in fiscal 2027, 13.22% in fiscal 2028, and 14.02% in fiscal 2029, while estimated P/E declines from 20.82 times fiscal 2027 earnings to 14.23 times fiscal 2030 earnings. Those expectations suggest investors anticipate sustained profit growth from the company’s expanding specialty-care operations, making acquisition returns increasingly important to the valuation.
Institutional positioning provides additional context. Hedge-fund ownership of McKesson increased from 73 to 77 funds in Q2, with D.E. Shaw and Citadel expanding their positions by 807% and 513%, respectively. Option Care’s hedge-fund ownership also increased, from 35 to 38 funds, including a 220% position increase by Point72 Asset Management. These changes preceded the acquisition announcement and therefore reflect positioning before the transaction became public. However, the rising number of hedge fund holders did not tell the entire story. See how hedge funds’ combined Option Care holdings fell from $861 million to $498 million, despite more funds owning the stock.
The 49% ownership structure allows McKesson to participate in Option Care’s future growth without initially acquiring the entire business, while retaining the possibility of full ownership later. That flexibility could prove valuable if the partnership improves profitability, but it also leaves McKesson exposed to the financial performance of another specialty-care investment.
For Option Care Health, Inc. shareholders, the immediate valuation question is whether the agreed acquisition price adequately compensates them for the company’s longer-term potential. For McKesson Corporation investors, the challenge is broader: demonstrating that its increasingly extensive specialty-care platform can produce sustained earnings growth and attractive returns on invested capital. The $5.8 billion transaction strengthens McKesson’s position in a growing healthcare market, but the ultimate investment case depends on converting that strategic position into incremental profits and cash flow. The $5.8 billion valuation could be justified if McKesson can accelerate Option Care’s modest growth and improve profitability, but its current financial performance alone does not establish a compelling case for the acquisition premium.
While we acknowledge the risk and potential of MCK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MCK and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk? and Can AbbVie’s Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation?
Hedge Fund Resource Center